Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 5/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.43 |
| ▸ | BAD | Q92934 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapoxetine SCHEMBL9614075 | 0.92 | KMT2A (0.59) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613984 | 0.90 | KMT2A (0.52) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613810 | 0.90 | KMT2A (0.52) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613876 | 0.89 | KMT2A (0.52) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613773 | 0.88 | KMT2A (0.50) | KMT2AKDM4EALDH1A1HPGDATM | |
| Dapoxetine SCHEMBL9613718 | 0.86 | KMT2A (0.50) | KMT2AKDM4EALDH1A1HPGDATM | |
| Oxalic Acid SCHEMBL9613860 | 0.86 | KMT2A (0.48) | KMT2AKDM4EALDH1A1HPGDATM | |
| Dapoxetine SCHEMBL3679561 | 0.86 | HTR1B (0.57) | KMT2AHTR1BCHRNB2CHRNB4CHRNA3 | |
| Dapoxetine SCHEMBL34479 | 0.86 | HTR1B (0.57) | KMT2AHTR1BCHRNB2CHRNB4CHRNA3 | |
| Dapoxetine SCHEMBL3672581 | 0.86 | HTR1B (0.57) | KMT2AHTR1BCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5135947-A | Treatment of depression, eating disorders, and alcoholism | ELI LILLY AND COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0288188-B1 | 1-PHENYL-3-NAPHTHALENYLOXY-PROPANAMINES | ELI LILLY AND COMPANY (US) | 1991-10-16 | — | — | EP | disclosed |
| EP-0288188-A1 | 1-Phenyl-3-naphthalenyloxy-propanamines | ELI LILLY AND COMPANY (US) | 1988-10-26 | — | — | EP | disclosed |